Sarcopenic Obesity Among Community Dwelling Elderly

Sarcopenic Obesity Clinical Trial

Official title:

Prevalence of Sarcopenic Obesity Among Community Dwelling Elderly: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04140864
• Other study ID #: UMFD3026-1
• Status: Completed
• Start date: December 3, 2018
• Est. completion date: May 14, 2019

Study information

• Verified date: October 2019
• Source: Universiti Tunku Abdul Rahman
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Sarcopenic obesity (SO) is a geriatric syndrome, characterized by reduced muscle mass and function, and increase in body fat. It is classified as a new category of obesity in elderly. It found to be associated with higher risk of physical disability, hospitalization, metabolic syndrome, cardiovascular disorders and mortality. According to the United Nations Economic and Social Commission for Asia and The Pacific's (UNESCAP) 2016 population data, Malaysians aged sixty and above contribute to 9.5% of the population. The aging individuals are estimated to reach 23.5% of the population by 2050. In the matter of human health, SO increases the risk of falls and fracture, deteriorates the performance of activities of daily living, enhances the risk of getting multiple health-related outcomes and results in physical disability. Eventually, the quality of life is adversely affected. In financial terms, SO cause significant burden to health care systems. Both hospitalization and cost of care during hospitalization are increased. Therefore, study of SO has experienced a revitalized research interest due to its negative impact on public health. In addition, there is significant lack of literature related to prevalence of SO in community-dwelling elderly in Malaysia, hence, a need to investigate this phenomenon.

Description:

Pilot study design was employed to determine the prevalence of sarcopenic obesity among community-dwelling elderly living in Kajang, Selangor. The sampling method used for recruitment of subjects was non-probability, convenient sampling. Sample size was calculated based on the work carrrid by Viechtbauer in 2015.

n=(In (1-y))/(In (1-π) ) where n = sample size π = problem probability y = level of confidence

The population of Kajang is approximately 428,131. The elderly population made up of about 9.5% of the total population in Malaysia based on the UNESCAP's 2016 population data. With confidence interval of 95% and margin of error 5%, The targeted sample size for this research study was set to be 59. Investigators recruited 65 subjects.

Measurements of the four diagnostic criteria for sarcopenic obesity were:

1. Muscle mass (skeletal muscle index - SMI) 2. Body Fat (percent body fat). Bioelectrical Impedance Analysis (BIA) device was used to measure muscle mass and percent body fat 3. Muscle strength (handgrip strength), and 4. Physical performance (usual gait speed).

The weight and height of all subjects were measured as BIA needed this data to quantify the muscle mass. Body weight and height were measured to the nearest 0.1kg and 0.01m using the calibrated stadiometer with electronic weighing scale. Before the measurements, the subjects were required to remove their footwear, accessories and excessive clothing, if any. After getting the readings for weight and height, body mass index (BMI) was calculated, to the nearest 0.01kg/m². Next, bioelectrical impedance analysis (BIA) device was utilized to analyze the subjects' body composition (SMI & percent body fat). Before body composition analysis, all subjects were informed to fast overnight and not to eat and drink anything before analyzing was carried out. All the respective subjects weight and height was inserted into the BIA device (Inbody S10 Body Composition Analyzer). The device operates with six different frequencies (1kHz, 5kHz, 50kHz, 250kHz, 500kHz, 1000kHz) at five segments of body, which are right arm, left arm, trunk, right leg and left leg. SMI, which is the height-adjusted appendicular skeletal muscle mass (ASM) of an individual was used to detect sarcopenia in the study subjects from the aspect of muscle mass. SMI (kg/m2) was calculated by dividing ASM (kg) with subject's height (m2). For ASM, the lean muscle mass of four limbs were added up. Scientific calculator was used to obtain the ASM and SMI of the subjects as these were not provided in the body analysis result sheet. Both the ASM and SMI were quantified to the nearest 0.01kg and 0.01 kg/m2 respectively.

Before starting body composition analysis, subjects were positioned in seated posture and touch type electrodes were fixed on their four limbs. They were asked to rest their forearms on the arm rest and kept their legs apart. Their feet must be flat on the floor. For electrode placements, hand electrodes will be placed over the index (black) and middle (red) fingers for both hands, whereas foot electrodes will be placed over the ankles (red for medial side; black for lateral side) for both feet. Alcohol swap was used to wipe subjects' ankles to moisture the skin over that area. Once the analysis began, the subjects were instructed to avoid any body movement and not to fall asleep throughout the process. The entire analysis process normally took 2-3 minutes.

Handgrip dynamometer (HGD) was used to evaluate the subjects' handgrip strength (HS). The model of HGD equipped was Jamar® Hydraulic Hand Dynamometer. The measurements were done for 3 times to get the average readings. HS was measured to the nearest 0.01kg. Standardized positioning recommended by the American Society of Hand Therapies (ASHT) were employed: subjects in sitting position with back supported, shoulders adducted, elbow flexed at 90°, forearm and wrist in neutral position. Subjects were instructed to hold the dynamometer and exert maximum force by dominant hand forcefully for 3 seconds. Demonstration was given before participants performed the maneuver. 1 minutes rest interval was given between each trial to prevent muscle fatigue.

Usual gait speed (GS) was measured by 6 meters walk test (6 MWT), as suggested by EWGSOP to assess the subjects' physical performance. Gait speed (GS) (meters/second) was calculated by dividing distance walked (m) with the time taken to finish the walkway (in seconds). Subjects were required to repeat the test for three times to obtain average reading. Time taken to complete the walkway was measured using timer in mobile phone to the nearest 0.1 seconds, whereas GS was measured to the nearest 0.1m/s. A walkway with distance of 10 meters was measured using measuring tape. Green colour cones were being positioned at the both end points of the walkway, with 2 and 8 meters marked with yellow colour cones. The first and last 2 meters were used as acceleration and deceleration phase respectively. The subjects were instructed to walk at their usual and comfortable pace. The timing was being started when the toes of leading foot cross 2-meter mark, and stopped once 8-meter mark was crossed. . The subjects were allowed to use assistive device, if any, during the gait test. Demonstration was given before the test. Several precautions were taken throughout the test; one of the researcher was walking half step behind the participants so their speed of walking will not be influenced, both researcher and subject were not allowed to talk and researcher must by the side of subjects to prevent them from falling. Besides, subjects were free to stop the test if they felt any discomfort but no such instance was reported.

Diagnostic algorithm was used as the principal guideline for diagnosis of sarcopenia adapted from Asian Working Group for Sarcopenia (AWGS) and European Working Group on Sarcopenia in Older People 2 (EWGSOP2). According to recommendations by AWGS, the cut-off values for SMI (kg/m2) are 7.00kg/m2 and 5.70 kg/m2 for male and female respectively were used to identify low muscle mass. For muscle strength, values of <26.00kg for male and <18.00kg were considered as low. In addition, poor physical performance was evaluated when the value for gait speed is <0.8m/s and it is not gender-specific. To define obesity, American Society of Bariatric Physicians (ASBP) suggested to use percent body fat of ≥25% for male and ≥30% for female.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: May 14, 2019
• Est. primary completion date: May 14, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Aged 60 and above

• Either gender

• Able to ambulate independently with or without walking aids

Exclusion Criteria:

• Individuals who are wheelchair bound.

• Individuals with metal implant (eg. Artificial pacemaker, joint arthroplasty)

• Individuals with skin lesions that restrict the use of BIA

• Individuals with amputation of limbs

• Individuals with hearing impairment and not using hearing aid

• Individuals with visual impairment and not using spectacles

• Individuals with fear of fall

Related Conditions & MeSH terms

• Obesity
• Sarcopenic Obesity

Locations

Country	Name	City	State
Malaysia	Universiti Tunku Abdul Rahman	Kajang	Selangor

Sponsors (1)

Lead Sponsor	Collaborator
Universiti Tunku Abdul Rahman

Country where clinical trial is conducted

Malaysia, 

References & Publications (11)

Batsis JA, Mackenzie TA, Barre LK, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. Eur J Clin Nutr. 2014 Sep;68(9):1001-7. doi: 10.1038/ejcn.2014.117. Epub 2014 Jun 25. — View Citation

Chan YY, Lim KK, Lim KH, Teh CH, Kee CC, Cheong SM, Khoo YY, Baharudin A, Ling MY, Omar MA, Ahmad NA. Physical activity and overweight/obesity among Malaysian adults: findings from the 2015 National Health and morbidity survey (NHMS). BMC Public Health. 2017 Sep 21;17(1):733. doi: 10.1186/s12889-017-4772-z. — View Citation

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 Feb;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025. — View Citation

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. — View Citation

Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G, Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S, Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011 May;12(4):249-56. doi: 10.1016/j.jamda.2011.01.003. Epub 2011 Mar 4. — View Citation

Hao Q, Hu X, Xie L, Chen J, Jiang J, Dong B, Yang M. Prevalence of sarcopenia and associated factors in hospitalised older patients: A cross-sectional study. Australas J Ageing. 2018 Mar;37(1):62-67. doi: 10.1111/ajag.12492. Epub 2018 Jan 5. — View Citation

Khambalia AZ, Seen LS. Trends in overweight and obese adults in Malaysia (1996-2009): a systematic review. Obes Rev. 2010 Jun;11(6):403-12. doi: 10.1111/j.1467-789X.2010.00728.x. Epub 2010 Mar 11. Review. — View Citation

Kim TN, Yang SJ, Yoo HJ, Lim KI, Kang HJ, Song W, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond). 2009 Aug;33(8):885-92. doi: 10.1038/ijo.2009.130. Epub 2009 Jun 30. — View Citation

Öztürk ZA, Türkbeyler IH, Abiyev A, Kul S, Edizer B, Yakaryilmaz FD, Soylu G. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. Intern Med J. 2018 Aug;48(8):973-981. doi: 10.1111/imj.13935. — View Citation

Suzana S, Kee CC, Jamaludin AR, Noor Safiza MN, Khor GL, Jamaiyah H, Geeta A, Ahmad Ali Z, Rahmah R, Ruzita AT, Ahmad Fauzi Y. The Third National Health and Morbidity Survey: prevalence of obesity, and abdominal obesity among the Malaysian elderly population. Asia Pac J Public Health. 2012 Mar;24(2):318-29. doi: 10.1177/1010539510380736. Epub 2010 Sep 10. — View Citation

Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):388-95. doi: 10.1016/j.numecd.2007.10.002. Epub 2008 Apr 18. Review. — View Citation

* Note: There are 11 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle Mass		Through Study completion, an average of 6 months.
Primary	Body fat percent		Through Study completion, an average of 6 months.
Primary	Hand-grip strength		Through Study completion, an average of 6 months.
Primary	Gait speed		Through Study completion, an average of 6 months.